Amgen ovarian cancer drug fails to improve overall survival

November 4, 2014 3:00 PM

2 0

(Reuters) - Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial.

Patients given the drug, trebananib, along with a chemotherapy agent paclitaxel, experienced overall survival of 19.3 months, compared with 18.3 months for the placebo group.

Also read: Poland's PKN Q3 net profit rises 92 pct y/y, more than expected

Read more

To category page